Natural interferon alfa for treatment of condylomata acuminata

The activity of natural (leukocyte) interferon alfa in the treatment of condylomata acuminata was assessed in a randomized, double-blind, placebo-controlled, multicenter trial. Interferon alfa (Alferon N Injection) or placebo was injected into lesions twice weekly for up to eight weeks. Eighty-six patients were given interferon alfa, and 72 were given placebo. Eighty-six percent of interferon alfa-treated patients and 89% of placebo-treated patients had received previous therapy for condylomata acuminata. Side effects, usually flulike symptoms, occurred briefly after the injections; if present, they disappeared before the end of the third week of therapy. Treatment completely eliminated warts in 62% of interferon alfa-treated patients compared with only 21% of placebo-treated patients. Natural interferon alfa given intralesionally is an effective and safe treatment even in patients with recurrent or recalcitrant genital warts.     

Treatment of chronic hepatitis C virus infection with interferon alfa and ribavirin: sustained response in two patients with transfusion dependent thalassaemia

We describe two cases of transfusion dependent thalassaemics with chronic hepatitis C virus infection whom were treated successfully with interferon and ribavirin, following failure of response or relapse after an initial response to interferon monotherapy. They had sustained virological response for more than twelve months after completing therapy. Transfusion requirements were significantly increased during the combination therapy, probably due to ribavirin-induced haemolysis. Serum ferritin level decreased significantly during the treatment. Combination therapy with interferon alfa and ribavirin may be a feasible treatment option for some nonresponders to prior interferon monotherapy.     

干扰素治疗病理性瘢痕的探讨

目的 寻找治疗病理性瘢痕有效的方法.方法 用干扰素局部或全身注射及外用干扰素药膏的方法治疗31例病理性瘢痕患者.结果 干扰素治疗31例病理性瘢痕,有效26例,无效5例.结论 局部、全身应用干扰素可治疗体表病理性瘢痕,疗效肯定.     

病灶周围注射干扰素α-2b单一疗法治疗基底细胞癌的长期随访

背景:干扰素α-2b(IFN)可作为手术或破坏性治疗的替代方法用于治疗基底细胞癌(BCC)。目的:本研究旨在确定IFN治疗BCC的长期效果。方法:1985—1992年间,总计有98处活组织检查证实为原发表浅及小结节BCC的50例患者接受了皮损周围皮内注射IFN治疗。结果:98处BCCs中有95处(51处小结     

Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C

A 47 year old man with chronic hepatitis C was treated with interferon alfa, 3 million units three times a week, and developed widespread plaque psoriasis within weeks of starting interferon therapy. There was no previous history of psoriasis. The psoriasis was characterised by extensive nail involvement and plaques at the interferon injection sites. The patient relapsed after a total of 12 months of interferon and was subsequently treated with interferon and tribavirin (ribavirin) with recurrence of the psoriasis.     

Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine

Human immunodeficiency virus (HIV)-related thrombocytopenia has been well described and requires therapy in about one half of the patients. Conventional modes of therapy with prednisone, danazol, immunoglobulin, and/or splenectomy have not been uniformly successful. We have administered zidovudine to three patients with HIV-related thrombocytopenia. All three patients responded with a sustained increase in their platelet counts, despite discontinuation of conventional therapy. Interruption of zidovudine therapy was associated with a decrease in platelet count. Concomitant with the elevation in platelet count with zidovudine therapy, there was a reduction in the circulating p24 antigen levels. Whether the elevations in the platelet count in these patients with HIV-related thrombocytopenia is due to the antiviral effect of zidovudine is unknown. It is clear that further studies examining the prospective use of zidovudine in the treatment of HIV-related thrombocytopenia are indicated.     

更昔洛韦眼用凝胶联合干扰素治疗单疱病毒性角膜炎

单纯疱疹病毒性角膜炎（herpes simplex keratitis,HSK）是由单纯疱疹病毒（herpes simples virus,HSV）引起的角膜炎症性损坏,其病程较长,易复发,是我国常见的致盲眼病之一。近年来,我科应用更昔洛韦眼用凝胶联合干扰素球结膜下注射治疗单疱病毒性角膜炎取得了良好的效果,现报告如下。     

α-干扰素联合护肝宁片治疗慢性乙型肝炎疗效观察

目的观察注射用重组人干扰素α-2b联合护肝宁片治疗慢性乙型肝炎临床疗效。方法将HBsAg、HBeAg和HBV-DNA同时阳性的62例慢性乙肝患者分为α-2b干扰素加护肝宁片的联合治疗组及单用α-2b干扰素的对照组,两组对比治疗,联合组34例,对照组28例,干扰素均为每周3次,每次5×106u,肌肉注射,半年为一疗程,护肝宁片每日3次,每次4粒,3个月,治疗结果进行总结。结果联合组总有效率91.2%,对照组为71.4%,统计学处理(P<0.05)有显著差异存在。联合组HBeAg和HBV-DNA转阴率分别为60.7%和60%,优于对照组。结论联合组慢性乙型肝炎不良反应少,疗效优于单一用药组。     

IFN-α治疗小儿乙型肝炎病毒相关性肾炎(附12例报告)

目的：观察α－干扰素（ＩＦＮ－α）对１２例小儿乙型肝炎病毒相关性肾炎的治疗效果。方法：先给予强的松１ｍｇ／（ｋｇ·ｄ）治疗２周后突然停药,此时开始应用ＩＦＮ－α１００万单位,隔天１次肌注,疗程共６个月。观察患儿血ＨＢＶ抗原的转变,尿蛋白及血生化的变化。结果：１０例患儿中的４例ＨＢｅＡｇ转阴,１２例患儿中的３例ＨＢｓＡｇ转阴,５例尿蛋白转阴,３例明显好转,总有效率为６６．７％（８／１２）。尤其是对病理类型为膜性肾病（ＭＮ）及系膜增殖性肾小球肾炎（ＭｓＰＧＮ）疗效较好,而对膜增殖性肾小球肾炎（ＭＰＧＮ）者则效果较差。结论：该剂量疗程的ＩＦＮ－α对小儿乙肝病毒相关性肾炎的治疗具有一定效果,适合我国国情,值得推广应用     

鼻腔吸入IFN-r治疗变应性鼻炎的实验研究

目的:探讨鼻腔吸入r干扰素(IFN-r)对变应性鼻炎(allergic rhinitis,AR)的防治作用。方法:采用卵清蛋白(OVA)、氢氧化铝建立大鼠AR模型。IFN-r鼻腔吸入组(C组)与模型建立第23~30天,每日1次鼻腔吸入IFN-r 12μg,第31天取鼻腔灌洗液测定细胞成分,白介素(IL)-4,IL-5浓度,取血测定血浆IgE水平。设正常对照组(A组),AR模型磷酸盐缓冲液(PBS)处理组(B组)和丙酸倍氯米松吸入组(D组),每组5只大鼠。结果:C组鼻腔灌洗液中的嗜酸性粒细胞(EOS)为(0.005±0.003)×104/ml,明显低于B组的(0.223±0.068)×104/ml(P<0.01);C组鼻腔灌洗液中的IL-4为(7.8±3.2)pg/mL,IL-5为(12.5±4.6)pg/mL,均明显低于B组(P<0.01);C组血浆中总IgE为(38.5±9.6)μg/ml,OVA特异性IgE为(19.6±5.2)U/mL,明显低于B组(P<0.01)。结论:鼻腔吸入IFN-r可以抑制AR鼠IL-4和IL-5的合成,抑制EOS在鼻腔内的炎性浸润及血浆中总IgE和OVA特异性IgE水平,因而,对AR具有一定的防治作用。     

多灶性淋巴管内皮肉瘤伴血小板减少症

多灶性淋巴管内皮肉瘤伴血小板减少症是一种非常罕见的疾病。本病表现为弥漫的先天性皮肤和胃肠道血管病变，可以导致严重的胃肠道出血和血小板减少。血管损害的组织病理和免疫组化研究证实为淋巴管内皮细胞起源。治疗效果常不满意。本文报道1例该病的罕见病例，患者为一4周大的婴儿。     

Brucellosis associated with thrombocytopenia

Brucellosis is a zoonotic disease and is endemic in Saudi Arabia. Many hematological complications have been reported. We report a case of selective thrombocytopenia in an expatriate from Bangladesh. Patient responded well to antibrucella and steroid treatment.     

干扰素联合大剂量胸腺肽治疗慢性乙型病毒性肝炎

目的：探讨干扰素联合大剂量胸腺肽对慢性乙型病毒性肝炎的治疗作用及机制。方法：按诊断标准选择慢性乙型病毒性肝炎100例，随机分为干扰素联合大剂量胸腺肽治疗组（50例）和干扰素对照组（50例），观察比较两组患者的转氨酶及HBeAg、HBVDNA的变化。结果：干扰素联合大剂量胸腺肽治疗组的转氨酶复常率，HBeAg及HBVDNA阴转率均明显高于对照组（P＜0.05)，结论：大剂量胸腺肽能促进HBeAg的阴转，抑制HBV的复制，提高细胞免疫应答能力；干扰素联合大剂量胸腺肽治疗慢性乙型病毒性肝炎有较好的疗效，且使用安全。     

蜚蠊提取液改善阴道微生态及治疗宫颈持续性高危型人乳头瘤病毒感染的研究

目的观察蜚蠊提取液联合干扰素对宫颈持续性高危型人乳头瘤病毒（high-risk human papillomavirus, HR-HPV）感染的治疗效果,并比较治疗前后阴道微生态及宫颈局部细胞免疫功能变化。方法按病例纳入和排除标准纳入宫颈持续性HR-HPV感染患者80例随机分为2组,每组40例,对照组使用干扰素阴道纳入治疗,研究组在对照组的基础上加用蜚蠊提取液进行阴道冲洗,两组均治疗3个疗程。在治疗前后分别进行宫颈HR-HPV检测、阴道微生态评价及宫颈细胞免疫功能检测。结果治疗后研究组宫颈持续性HR-HPV感染转为阴性24例（61.54%）,对照组转为阴性13例（33.33%）,研究组治疗宫颈持续性HR-HPV感染的效果明显优于对照组（χ2=6.221,P=0.013）;研究组治疗后阴道微生态失衡（χ2=6.642,P=0.010）、乳杆菌分级异常（Ⅱb或Ⅲ级,χ2=6.271,P=0.012）、革兰阴性短杆菌（χ2=7.508,P=0.006）、革兰阳性球菌（χ2=8.419,P=0.004）、pH值异常（χ2=4.198,P=0.040）、H2O2阳性（χ2=5.769,P=0.016）及AV检出（χ2=4.255,P=0.039）等指标较治疗前得到明显改善（P＜0.05）;对照组治疗后仅在pH值异常改善方面与治疗前差异有统计学意义（χ2=7.429,P=0.006）;两组间治疗后比较,研究组对阴道微生态失衡的治疗效果较对照组更明显,具有显著性差异（χ2=4.446,P=0.035）;治疗后研究组宫颈细胞免疫功能改善比对照组更明显,CD4（t=-4.741,P＜0.001）、CD8（t=-4.725,P＜0.001）、CD4/CD8（Z=-5.022,P＜0.001）、TNF-α（t=-4.912,P＜0.001）、IL-4（t=-2.162,P=0.034）差异均具有统计学意义（P＜0.05）。结论蜚蠊提取液清利湿热、活血解毒等功效,与干扰素合用可显著提高宫颈持续性HR-HPV感染的治疗效果,其作用可能与通过纠正阴道微生态失衡及改善宫颈局部细胞免疫功能相关。     

干扰素治疗慢性乙型肝炎40例疗效分析

干扰素与免疫调节肽治疗慢性乙型肝炎各40例,结果表明:干扰素组有效率为72.5％,免疫调节肽组有效率为67.5％(P>0.05),无显著差异,免疫调节肽价格较便宜,值得进一步研究。     

雾化吸入γ干扰素阻断GATA-3表达治疗支气管哮喘

目的研究雾化吸入γ扰素(IFN-γ)对支气管哮喘的防治作用及机制。方法采用卵蛋白(OVA)、氢氧化铝建立BALB/c小鼠哮喘模型。IFN-γ雾化吸入组(C组)于模型建立第23天至第30天每日1次雾化吸入IFN-γ12μg,第31天取肺泡灌洗液(BALF)测定细胞成分、白介素(IL)-4、IL-5浓度,取血测定血浆IgE水平,观察肺组织病理学变化及转录因子GATA-3的表达。设正常对照组(A组)和哮喘模型磷酸盐缓冲液(PBS)处理组(B组)。每组12只小鼠。结果C组BALF中的嗜酸性粒细胞(EOS)为0．005±0．003,明显低于B-组的O．211 4-O．067(P<0．01);C组BAI。F中的IL-4为(6．8±3．7)pg／mL,IL-5为(12．6±4．8)pg/mL,均明显低于B组的(90．5±22．4)pg/mL和(55．6±10．7)pg/mL(P＜0．01);C组血浆中总IgE为(38．8±9．7)μg/mL,OVA特异性IgE为(19．2±4．8)U/mL,明显低于B组的(67．2±9．7)μg/mL和(34．6±7．8)U/mL(P＜0．01);B组支气管平滑肌肥厚,黏膜充血、水肿．黏膜层增厚,并有EOS为主的炎性细胞浸润,管腔内可见黏液栓,支气管壁周围有EOS为主的炎性细胞浸润,而C组小鼠的上述炎症性改变明显减轻;免疫组织化学显示B组肺组织中GATA-3的表达明显增加。而C组GATA-3的表达明显减少。结论雾化吸入IFN-γ可以抑制哮喘鼠IL-4、IL-5的合成、抑制气道炎症、抑制EOS在气道内的炎性浸润及血浆中总IgE和OVA特异性IgE水平,其机制可能与IFN-γ阻断GATA-3的表达,从而继发抑制辅助性T细胞2型反应有关。     

干扰素α-1b联合利巴韦林治疗慢性丙型肝炎64例

目的　观察干扰素α - 1b(IFNα - 1b)与利巴韦林 (ribavirin)联合治疗慢性丙型肝炎 (CHC)的疗效及安全性。方法　 6 4例CHC随机分为联合治疗组 (IFNα - 1b 加利巴韦林 ,30例 )与对照组 (单用IFNα - 1b,34例 ) ,观察两组治疗前后的疗效和毒副作用。结果　联合治疗组临床症状体征的缓解率为 93.33% ,病毒应答率为 6 3.33% ;对照组分别为 85 .30 %、47.0 6 % ,两组无显著差异 (P >0 .0 5 )。随访 6个月联合治疗组的持续应答率为 40 .0 0 % ,对照组为 14.71% ,有显著差异 (P <0 .0 5 )。联合治疗组副作用除贫血较对照组明显外 ,其他与对照组相仿。结论　干扰素联合利巴韦林治疗CHC较单用干扰素远期疗效显著且耐受性好     

检测丙型肝炎患者治疗前后血清HCV RNA含量和ALT水平的应用价值

目的探讨丙型肝炎患者血清丙型肝炎病毒核糖核酸(HCVRNA)含量和丙氨酸氨基转移酶(ALT)水平与干扰素治疗效果的关系。方法应用荧光定量聚合酶链反应(FQ—PCR)测定HCV RNA的含量,速率法测定血清ALT水平,测定了16例丙型肝炎患者α-干扰素治疗前和治疗三个月、治疗六个月的HCV RNA含量和ALT水平。结果16例丙型肝炎患者经治疗三个月和六个月HCVRNA含量和ALT水平均显著下降(P<0.05)。经六个月治疗有11例患者(68.8%)HCVRNA含量很低或为零,ALT正常,视为干扰素完全反应者;另外5例为部分及无效反应者。结论FQ—PCR定量准确,用其测定血清HCVRNA含量合并血清ALT水平一起作为丙型肝炎疗效观察指标,对临床制定合理的治疗方案有重要意义。